Harbour BioMed partners with Bristol Myers Squibb on antibody development

Harbour BioMed (HKEX: 02142) announced a multi-year global collaboration and license agreement with Bristol Myers Squibb to discover and develop multi-specific antibodies, according to a company statement.

Under the agreement, Harbour BioMed could receive payments totaling $90 million, plus development and commercial milestones of up to $1.035 billion, along with tiered royalties if Bristol Myers Squibb advances all potential programs.

The collaboration will utilize Harbour BioMed's Harbour Mice technology platform for antibody discovery programs. The partnership may also leverage Harbour BioMed's development capabilities to conduct early clinical trials in China.

"We are delighted to collaborate with Bristol Myers Squibb to advance next-generation multi-specific antibody discovery and development," said Jingsong Wang, founder, chairman, and CEO of Harbour BioMed. "This collaboration leverages our Harbour Mice fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential."

Harbour BioMed is a biopharmaceutical company focused on discovering and developing antibody therapeutics in immunology and oncology. The company's Harbour Mice platform generates fully human monoclonal antibodies in both traditional and heavy chain only formats.

You May Also Be Interested In

• Canadian Solar names Dylan Marx to lead Recurrent Energy subsidiary
• Curtiss-Wright plans $80M expansion at Pennsylvania facility
• CervoMed (CRVO) for 10.08M share offering by selling stockholders